In addition to these findings, a study found that ribociclib plus letrozole resulted in greater cost‐savings than other CDK4/6 inhibitor‐letrozole combination making it a cost‐effective treatment for ER‐positive BC.119. This evidence concerns the gene CDK4 and breast cancer.